Targeting Prostate Cancer with Multifunctional Nanoparticles
Abstract
Prostate cancer cells were transfected with claudin siRNA duplexes using Lipofectamine RNAiMAX (Invitrogen) as well as the appropriate controls including vehicle, non-targeting siRNA (siSC5) (negative control) and glyceraldehyde-3-phosphate dehydrogenase (GAPD) (positive control). A time course and concentration curve was completed to determine the maximum down-regulation of claudin-3 and claudin-4 expression. In addition, cytotoxicity assays were performed to determine the number of viable prostate cancer cells upon claudin-3 siRNA or claudin-4 siRNA treatment. We were able to get great knockdown, which translated into a decrease in the number of viable prostate cancer cells by testing each target with 4 independent siRNAs for claudin-3 and claudin-4. In looking at our claudin-4 siRNA data, we treated prostate cancer cells in vitro for 72 hours, at concentrations of 25, 50 and 100 nM (Fig 2, top). As can be seen from our data, there was approximately a 60% decrease in cell viability upon treatment with claudin-4 siRNA. In addition, our immunohistochemical data demonstrate that claudin-3 and claudin-4 are expressed in subsets of aggressive prostate cancer. Finally, we produced our first two batches of nanoparticles during year 1 and we were able to show that these nanoparticles bind to prostate cancer cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2015
- Accession Number
- AD1000976
Entities
People
- Darryl Martin
Organizations
- Yale University